Analysis of PRO-DMD-01 Functional Data to Inform Endpoints in Wave’s FORWARD-53 Study of WVE-N531 for Duchenne Muscular Dystrophy (DMD) Exon-53 Skipping Therapy

A Vivli admin revised the lay summary so it is more suitable for a lay audience and provide background information on the condition and necessity of the research:

Duchenne muscular dystrophy (DMD) is a rare, genetic disorder that causes progressive muscle weakness and loss of function. DMD is caused by mutations in the dystrophin gene, which leads to the absence of a protein essential for muscle health. Approximately 1 in 5,000 males worldwide are born with DMD. It significantly impacts quality of life and life expectancy, with most patients requiring a wheelchair by their early teens and experiencing severe complications later in life.

There is no cure for DMD, but therapies targeting specific mutations in the dystrophin gene, such as exon skipping therapies, show promise in slowing disease progression. Exon skipping therapies are treatments that help the body produce a working version of a protein by skipping over the faulty part of a gene, and aim to restore production of a shorter, yet partially functional, form of the dystrophin protein. WVE-N531 is an exon skipping treatment being developed for patients with DMD who have mutations treatable by exon 53 skipping.

The purpose of this research is to analyze data from the PRO-DMD-01 study. The results from this research will be used as an external control to compare against the corresponding data collected in the FORWARD-53 study sponsored by Wave Life Sciences. FORWARD-53 is a small (N=11), single-arm study of WVE-N531. Wave plans to use the results generated under this research plan for PRO-DMD-01 to assess activity of WVE-N531 in FORWARD-53.

To conduct this research, we will analyze functional outcomes data, such as measures of muscle strength and mobility.